Similarly, the administration of single-agent anti-CTLA4 (median time to endpoint: IgG 12 days, anti-CTLA4 11 days; Figure 3c) and anti-PDL2 (median time to endpoint: IgG 14 days, anti-PDL2 13.5 days; Figure 3d) did not achieve significant a tumor growth delay compared to their respective isotype controls. The gene discussed is PDCD1LG2; the disease is neoplasm.